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INTRODUCTION
Osteosarcoma is the most common primary malignant bone
tumor in children and young adults. The overall survival rate
remains around 60–70%. Survival rates in patients with pulmonary
metastases are generally less than 30%. Approximately, one-third of
patients with only local disease at diagnosis will relapse with
pulmonary metastases [1]. Over the last 20 years, there have been
few changes in standard chemotherapy treatment regimens for
patients with osteosarcoma.
In normal bone, insulin-like growth factor (IGF) signaling is
involved in osteogenesis and bone homeostasis [2]. While there is no
conclusive evidence published to date to implicate IGF-1 and/or
IGF-2 in autocrine growth in osteosarcoma, consistent expression of
IGF-1R, IGF-1, and IGF-2 has been reported in osteosarcoma cell
lines and patient samples [3]. Evidence of IGF-mediated growth
in osteosarcoma can be inferred from experiments demonstrating
inhibition of growth and metastases of murine osteosarcoma
following hypophysectomy [4], and inhibition of tumor growth in
xenografts following treatment with anti-IGF-1R antibody. Addi-
tionally, an increased risk of osteosarcoma is reported among
patients with a single nucleotide polymorphism in IGF2R suggest-
ing a possible role for this variant IGF-2R in the pathogenesis of
osteosarcoma [5].
IGF-1R is capable of binding both IGF-1 and IGF-2, leading to
autophosphorylation of the receptor. When IGF-1R is phosphory-
lated, insulin receptor substrates 1–4 (IRS1–4) and the Src
homology collagen-like adaptor protein (Shc) can initiate intra-
cellular signaling cascades. Phosphorylated IRS-1 activates the p85
regulatory subunit of phosphatidylinositol 3-kinase (PI3K). When
the p85 and p110 subunits of PI3K bind to IRS, phosphatidylino-
sitol-4,5-biphoshate is converted to phosphatidylinositol-3,4,5-
biphoshate (PIP3). Phosphoinositide-dependent kinase-1 is then
activated by PIP3, resulting in phosphorylation and activation of the
serine/threonine kinase AKT. Substrates responsible for the diverse
functions of AKT include glycogen synthase kinase-3, involved in
enhancing intracellular metabolism; the mammalian target of
rapamycin (mTOR), involved in protein synthesis and cell growth;
BAD (a Bcl-2 family member), involved in cell survival; and
p28Kip1, involved in cell proliferation. Regulation and inhibition of
PI3K signaling may be mediated in part by S6K, which when
activated by mTOR, phosphorylates the serine residues on IRS-1,
thus marking it for degradation [6,7]. In parallel to the signaling
activated though PI-3K, Shc activates Ras. Once activated, Ras
initiates signaling through Raf, which ultimately leads to activation
and phosphorylation of the mitogen-activated protein kinase-1 and
-2 (MAPK) through the MAPK/ERK kinases (MEK1 and MEK2)
[6]. Activation of MAPK through Ras results in enhanced
proliferation, migration, and survival [6,7].
It has been known for 20 years that IGF signaling is important to
the growth and survival of sarcomas [8]. The recent development of
Background. The combination of rapamycin and R1507, a fully
human IgG1 monoclonal antibody targeting the IGF-1 receptor (IGF-
1R), in osteosarcoma xenograft tumors in vivo is evaluated in this
report. Procedure. Six osteosarcoma xenograft tumor models were
evaluated for growth inhibition after monotherapy with R1507,
rapamycin, and the combination of both drugs. Phosphorylation of
proteins involved in IGF-1R signaling is evaluated at various time
points by immunoblotting. Results. IGF-1R was expressed in five of
the six human osteosarcoma tumor lines. Objective responses to
R1507 were seen in four of the six tumor lines (OS1, OS2, OS9, and
OS17) including one complete response in OS1. IGF-1R protein
levels did not predict degree of response to R1507 in the sensitive
tumors. However, in one of the two R1507-resistant tumors (OS33),
there was a minimal expression of IGF-1R. An increase in AKT
phosphorylation was observed in all the osteosarcoma tumors
treated with rapamycin. However, phosphorylation of AKT was
inhibited when rapamycin was used in combination with R1507. In
three of the xenograft tumor lines, there was an improvement in
response when R1507 was used in combination with rapamycin.
Conclusions. IGF-1R inhibition by R1507 induced tumor growth
delays and improvement in event-free survival in four of six osteo-
sarcoma xenograft tumor lines. R1507 negates increased signaling
through AKT in response to mammalian target of rapamycin
inhibition, suggesting that the combination is worthy of further
evaluation in patients. As R1507 and other IGF-1R inhibitors
advance in clinical trials, it will be important to understand
biomarkers of response and pathways of resistance. Pediatr Blood
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monoclonal antibodies capable of inhibiting the binding of IGF-1
and IGF-2, and small molecules capable of inhibiting signaling
through IGF-1R without excessive toxicity, has generated renewed
interest in defining the validity of this target and biomarkers for
response. There are currently at least six human or fully humanized
anti-IGF-1R monoclonal antibodies currently in clinical trials, each
binding to the IGF-1R receptor and inhibiting ligand binding. There
are as well small molecules that target IGF-1R kinase domain.
However, markers for activity and resistance to IGF-1R inhibitors in
osteosarcoma are neither known, nor is there an understanding of the
cellular events that take place following IGF-1R inhibition in
osteosarcoma. To utilize potent inhibitors of IGF-1R signaling
effectively, it is important to understand the specific cellular events
that predict sensitivity or offer a means for tumors to salvage
effective growth signaling in the absence of IGF-1R activation.
In this current report, the fully human monoclonal antibody R1507
is evaluated in a panel of pediatric osteosarcoma tumor lines,
both alone and in combination with mTor inhibitor rapamycin.
As previously reported in other sarcomas, rapamycin increases
signaling through AKT in a manner dependent on IGF-1R [9].
R1507 inhibits this activation in all tumor lines evaluated and
improves response in two of the lines.
METHODS
Tumor Lines and Reagents
The OS1, OS2, OS9, OS17, OS31, and OS33 human osteo-
sarcoma tumor lines were generously provided by the Pediatric
Preclinical Testing Program. These lines are maintained by serial
passage in severe combined immune deficient (SCID) mice as
described previously by the Pediatric Preclinical Testing Program [10].
R1507 was provided by Roche Diagnostics GmbH (Discovery
Oncology, Penzberg, Germany). R1507 was at a stock concentration
of 25.6 mg/ml. For administration to the mice, the stock solution was
diluted in sterile saline and administered weekly for 6 weeks at a
dose of 10 mg/kg via intraperitoneal injection. Rapamycin was
purchased from LC Laboratories (Woburn, MA) and dissolved in
DMSO to a 5% solution. Rapamycin was further diluted in 5%
Tween 80 in water and administered to mice via intraperitoneal
injection daily five times for six consecutive weeks at a dose of
5 mg/kg/day.
Immunoblotting
At specified time points, mice were sacrificed with CO2, and
tumors immediately harvested on ice. The tumors were then lysed in
RIPA with buffer complete protease inhibitor cocktail G and
phosphatase inhibitor cocktail 1 and 2 (Sigma, St. Louis, MO). The
protein concentrations of the tumor lysates were determined by the
BCA protein assay (Pierce, Rockford, IL). Twenty micrograms of
protein from the lysates was resolved by SDS–PAGE and
transferred to nitrocellulose membranes. Membranes were blocked
with 5% milk in TBS-Tween 20 and then incubated with various
primary antibodies overnight at 48C. HRP-conjugated anti-rabbit
secondary antibody (Cell Signaling Technology, Cambridge, MA)
was used to detect protein-bound primary antibody. Bound
secondary antibody was detected by using Amersham ECL Plus
western blotting detection reagents (GE Healthcare, Piscataway,
NJ). The blots were then exposed to a Kodak Biomax Light Film.
For immunoblotting, antibodies against AKT, phospho-AKT
(Ser473), IGF-1R beta, MAPK p44/p42, phospho-p44/42 MAPK
(Thr202/Tyr204), S6 ribosomal protein, and phospho-S6 ribosomal
protein (Cell Signaling Technology) were used.
Animal Studies
Five- to 6-week-old female CB17 SCID mice (Taconic Farms,
Germantown, NY) were used for the in vivo experiments using
methodology previously described [10]. When implanted xenograft
tumors reached a volume between 200 and 500 mm3, the mice
bearing tumors were randomized into treatment groups consisting of
8–10 mice. All mice were maintained under barrier conditions, and
experiments were conducted using protocols and conditions
approved by the institutional animal care and use committee of
the Albert Einstein College of Medicine of Yeshiva University.
Tumor growth was assessed weekly for the duration of the study
initiation (6 weeks unless otherwise specified). Tumor volumes
were assumed to be spherical, and calculated from the formula
(p/6) d3, where d represents the mean diameter. Responses were
determined using tumor volume treatment/control (T/C), event free
survival T/C, and objective response criteria as defined previously
[10]. An event is defined as (1) death, (2) a reduction in starting body
weight of 20%, or (3) a relative tumor volume (RTV) greater than or
equal to 4, where the RTV is the volume on the day of measurement
divided by the volume on day 0 of treatment (starting volumes were
0.2–0.3 cm3). Animals reaching an RTVof 4 prior to the completion
of the 6-week experiment were euthanized and the event was
recorded.
Using criteria defined previously by Houghton et al. [10],
progressive disease is defined as less than 50% regression from
original tumor volume for the entire study period (RTV> 0.5) and
greater than 25% increase in tumor volume at the end of the study
period (RTV> 1.25). Stable disease is defined as tumor regression
that did not exceed 50% of the original tumor volume throughout the
entire study period (RTV> 0.5) and less than 25% increase in tumor
volume at the end of the study period (RTV< 1.25). A partial
response is defined as greater than 50% regression in tumor volume
(RTV< 0.5) but with a measurable tumor mass of greater than
0.10 cm3. Loss of measurable tumor mass (<0.10 cm3) at any point
during the treatment period (6 weeks) was defined as a complete
response (CR). A maintained CR was defined as a loss of measurable
tumor mass (<0.10 cm3) at any point after initiation of therapy
without re-growth during the 6-week study period.
Statistical Methods
RTV values were compared with the nonparametric Wilcoxon
rank sum test with Bonferroni’s correction. The survival analysis for
each treatment was determined using the Kaplan–Meier method.
Pairwise comparisons of the Kaplan–Meier curves were performed
by a log-rank test with Bonferroni’s correction. The difference was
considered to be significant when the P value was less than 0.05.
RESULTS
R1507 Inhibits Growth of Human
Osteosarcoma Xenografts
Tumor responses to R1507 treatment are presented in Figure 1.
The OS1, OS2, OS9, and OS17 tumors all had tumor growth delays
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with statistically significant improvements in event-free survival
and day 22 median tumor volumes (Table I). There was minimal
change in tumor growth in the OS31 and OS33 tumors with no
effect on event-free survival. These results are consistent with the
previously published reports with other IGF-1R directed antibodies
in the same tumor panel [11,12].
Treatment of OS1 and OS17 with R1507 for 6 weeks and
observation for an additional 6 weeks are shown in Figure 1e,f. In
Pediatr Blood Cancer DOI 10.1002/pbc
Fig. 1. Xenograft growth curves for osteosarcoma xenografts treated with R1507. The relative tumor volume (RTV) is calculated as the ratio of
tumor volume on the day of measurement divided by the tumor volume on day 0. Mice were treated with R1507 weekly at a dose of 10 mg/kg for a
total of 6 weeks. For OS2 (a), OS9 (b), OS31 (c), and OS33 (d), the experiment ended at the completion of the 6-week treatment period. OS1 (e) and
OS17 (f) were observed for a total of 12 weeks without additional treatment after week 6. Control-treated mice received only vehicle on same
schedule. Statistical analysis is listed in Table I.
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OS1, the CR was maintained for 6 weeks after R1507was
discontinued. Three of the ten OS1-treated mice had palpable
tumors (all less than 0.05 cm3, and still meeting the criteria for a
CR). During weeks 6–12 of the experiment, at which time no R1507
was administered, these tumors continued to grow, albeit at a slower
rate than controls. Likewise, the slope of the curve for OS17 did not
change when R1507 therapy was discontinued. There was clearly
tumor growth, but at a slower rate than the controls. This inhibition
of growth rate persisted 6 weeks after the last treatment. There were
no drug-related toxicities noted in the treated mice.
IGF-1R Expression Does Not Predict Sensitivity to
IGF-1R Inhibition in Osteosarcoma
IGF-1R expression in the osteosarcoma xenograft lines as
visualized by immunoblotting is presented in Figure 2. These data
Pediatr Blood Cancer DOI 10.1002/pbc
TABLE I. Summary of Tumor Response to R1507
Tumor
Kaplan–Meier estimate of
median time to event P value
Day 22 tumor volume
(treated/control) P value
OS1a Control 36 days <0.0001 0.06 <0.0001
Treated >EPb
OS2 Control 15 days <0.0001 0.20 <0.0001
Treated 29 days
OS9 Control 22 days <0.0001 0.31 <0.0001
Treated >EP
OS 17a Control 22 days <0.0001 0.40 <0.0001
Treated >EP
OS31 Control 22 days 0.95 1.02 1.00
Treated 22 days
OS33 Control 15 days 0.24 0.93 0.68
Treated 15 days
aAnimals observed for a total of 12 weeks following a total of 6 weeks of treatment; bEP is experimental
period. For OS2, OD9, OD31, and OS33, the tumors were followed for the 6 weeks of treatment. For OS1 and
OS17, the tumors were followed for an additional 6 weeks (12 weeks total) to observe the duration of
response.
Fig. 2. Determination of IGF-1R expression in xenograft tumors treated with R1507. a: The maximal response to R1507 is depicted in the table,
along with the corresponding constitutive IGF-1R expression. These immunoblots represent constitutive expression of IGFR in untreated tumors at
volume of 0.5 cm3. CR, complete response; PD, progressive disease. *Response where there was a statistically significant improvement in event-free
survival. b: Mice received either vehicle or a single dose of R1507 (10 mg/kg) on day 0. Tumors were harvested and snap frozen on days 2 and 7.
Immunoblotting for total IGF-1R was performed.
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Fig. 3. Determination of osteosarcoma xenograft response to R1507 in combination with rapamycin. Tumor-bearing mice were randomized
into one of four treatment groups and received either vehicle R1507 10 mg/kg/week IP for 6 weeks, rapamycin 5 mg/kg/day IP 5 days per week
for 6 weeks or the combination of rapamycin and R1507. Each data point is the median of 8–10 mice per treatment group. Statistical analysis is
detailed in Table II.
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correlate to the publicly available RNA expression (data not shown)
using the Affymetrix U133 Plus 2.0 chip [11,13]. OS33 has low level
expression of IGF-1R and is insensitive to all the three antibodies.
However, in the four R1507 sensitive lines, expression did not
correlate with response. The OS1 tumor was most sensitive to
R1507 with a CR. Compared to the other xenograft tumors, OS1
had intermediate receptor expression. OS2 had the highest level of
expression by immunoblotting, and yet demonstrates progressive
disease in response to R1507 treatment.
A decrease in IGF-1R expression was seen in three of the four
R1507 sensitive cell lines (OS1, OS2, OS9, but not OS17) with
R1507 therapy.
Following Inhibition of mTor, Osteosarcoma Tumor
Lines Induce Alternate Pathways to Salvage
Oncogenic Growth Signaling
In data published previously, the Pediatric Preclinical Testing
Program demonstrated that rapamycin (a specific inhibitor of
the mTOR/raptor complex) inhibits growth of the same xenografts
presented in this report [14]. It has also been previously reported in
sarcomas that rapamycin may induce phosphorylation of AKT in a
manner dependent on IGF-1R, thus increasing the dependency of
the tumor on IGF-1R mediated signaling [15–17]. Figure 3 shows
the results of the rapamycin in combination with R1507 in the OS
xenograft lines. In OS2, OS9, and OS31, there was an increase in
activity of the combination when compared to either drug alone
(Table II). In each of these lines, the day 22 RTV in the combination
arm is significantly smaller than the other treatment arms. While not
demonstrating a difference at day 22, in OS17 on day 42, the RTV in
the combination is significantly smaller than the other treatment
arms. In the OS1 tumor lines, there is a CR with R1507 alone, and
no additional effect of the combination. In OS33, there seems to be
no enhanced activity with the combination at day 22. There were no
drug-related toxicities noted in the treated mice.
Figure 4 demonstrates that rapamycin does induce phosphor-
ylation of AKT in all of the xenograft tumor lines. When R1507
was added to the rapamycin therapy, signaling through both AKT
and ribosomal S6 kinase (as a marker of mTOR activation) was
inhibited.
Signaling Through the Ras/MAPK Pathway May
Predict Susceptibility of Osteosarcoma Cells to
IGF-1R Signaling
In the OS31 and OS33 xenograft tumor lines, neither of which
has demonstrated a response to R1507, there was an increase in
MAPK phosphorylation on day 2 and 7 after a single treatment with
the IGF-1R antibody (Fig. 4e,f). These data imply that signaling
through MAPK may be induced when signaling though IGF-1R is
inhibited.
The increase in MAPK phosphorylation in response to R1507
may be dependent on signaling through mTOR. On day 2 and 7 of
treatment with rapamycin alone, MAPK phosphorylation was
diminished in all tumor lines. On day 2 of the combination
treatment, there was partial decrease in MAPK phosphorylation in
OS31, and a significant decrease in OS33.
In the four tumor lines sensitive to R1507, there is either a
decrease or no change in MAPK phosphorylation. In the OS1 tumor
line, there was complete tumor regression following administration
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TABLE II. Summary of Tumor Response to R1507 and Rapamycin
Tumor
Kaplan–Meier estimate of
median time to event P valuea
Day 22 tumor volume
(treated/control) P valuea
OS1a Control 36 days <0.0001
Rapamycin >EP 0.20 0.73 0.001
R1507 >EP 1.0 0.40 1.00
Combination >EP 0.35
OS2 Control 15 days <0.0001 <0.0001
Rapamycin >EP 0.63 0.14 <0.0001
R1507 32 <0.0001 0.20 <0.0001
Combination >EP 0.07
OS9 Control 22 days <0.0001 <0.0001
Rapamycin 38.5 days 0.002 0.39 0.017
R1507 >EP 1.0 0.37 0.003
Combination >EP 0.24
OS17a Control 22 days <0.0001 <0.0001
Rapamycin >EP 1.00 0.21 1.00
R1507 >EP 1.00 0.24 0.84
Combination >EP 0.18
OS31 Control 22 days 0.002 0.002
Rapamycin 22 days 0.066 0.76 0.009
R1507 22 days 0.006 0.97 0.002
Combination 29 days 0.58
OS33 Control 14 days <0.0001 <0.0001
Rapamycin >EP 1.0 0.18 1.0
R1507 15 days <0.0001 0.27 <0.0001
Combination 29 days 0.018
EP, experimental period, 6 weeks for all experiments. aP-value of the combination group compared control,
rapamycin or R1507 groups.
72 Kolb et al.
of the R1507 anti-IGF-1R antibody. Seven days after treatment with
R1507 alone, there was inhibition of AKT, ribosomal S6 kinase and
MAPK phosphorylation at Thr202/Tyr204 (Fig. 4a). In the OS2 and
OS9 tumor lines, there was also a decrease in AKT phosphorylation,
at least a transient decrease in S6 kinase phosphorylation, and a
decrease, in MAPK phosphorylation (Fig. 4b,c). In OS17, there was
no change in MAPK phosphorylation with R1507.
DISCUSSION
In six well-characterized osteosarcoma xenograft tumor lines,
R1507 has anti-tumor activity consistent with the published results
of two other monoclonal antibodies targeting IGF-1R [11,12]. For
each of the three anti-IGF-1R antibodies we have evaluated, there
is anti-tumor activity in the OS1, OS2, OS9 and OS17 tumors,
Pediatr Blood Cancer DOI 10.1002/pbc
Fig. 4. Correlation of signaling through AKT and mTor with response in tumor treated with R1507 and rapamycin. Tumors were harvested and
snap frozen from three mice in each treatment group as in Figure 3 on days 0, 2, and 7. All immunoblots were performed in triplicate and
representative results are shown. Immunoblots for OS 1 (a), OS 2 (b), OS9 (c), OS17 (d), OS31 (e), and OS33 (f) are presented.
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and minimal activity in OS31 and SO33. It has been reported in
Ewing sarcoma and rhabdomyosarcoma that inhibition of mTOR
may increase the dependency of tumors on IGF signaling [9,15,17].
Kurmasheva et al. [9]. recently showed that inhibitors of IGF-1R act
synergistically with rapamycin in sarcoma xenografts by inhibiting
hyperphosphorylation of AKT in response to mTOR inhibition.
In the current report, R1507 inhibits the induction of AKT
phosphorylation by rapamycin, and in three of the six tumor lines
there is enhanced anti-tumor effect.
R1507 induces statistically significant improvements in event-
free survival in OS1, OS2, OS9, and OS17, including a CR in OS1.
In the R1507-sensitive tumors, OS1, OS2, and OS9 phosphorylation
of AKT and S6 kinase are inhibited by R1507. In the OS17 tumor,
total AKT and total S6 ribosomal protein, as well as phospho AKT
and phospho S6 kinase are increased with R1507 treatment. The
mechanism of the anti-tumor effect of R1507 in this tumor is being
further evaluated.
We demonstrate that in the two R1507-resistant xenograft tumor
lines, phosphorylation of MAPK is induced within 7 days of a single
dose of antibody. Interestingly, this effect seems to be dependent on
signaling through mTOR, as evidenced by the fact that R1507-
induced MAPK phosphorylation is inhibited by rapamycin. In the
sensitive tumor lines, constitutive MAPK phosphorylation is
decreased (OS1, OS2, and OS9) or remains the same (OS17) with
R1507 treatment. Rapamycin has been shown to partially suppress
p44/42 MAPK activation by serum in melanoma cells [18].
Harwood et al. [19] recently demonstrated that the mTOR–raptor
complex (mTORC1) has a complex regulatory role in MAPK
signaling. In rhabdomyosarcoma lines, mTORC1 modulates
phosphorylation of MAPK at Thr202 through protein phosphatase
2A [19]. The mechanism by which MAPK phosphorylation is
increased by R1507 in osteosarcoma tumors consistently resistant to
IGF-1R inhibitors is currently under investigation.
In the osteosarcoma tumor lines evaluated in this report, IGF-1R
expression does not predict response to R1507. These data are not
consistent with the report by Cao et al. [16]. who recently showed, in
rhabdomyosarcoma tumors, that sensitivity to anti-IGF-1R anti-
body therapy corresponds directly to IGF-1R receptor level. In
osteosarcoma, there may be more robust markers for response than
receptor expression. Illustrating this point is the fact that the OS1
tumor demonstrated a CR to R1507 but with intermediate receptor
expression. The OS2 tumor has high receptor expression with
progressive disease in response to R1507, albeit with an improve-
ment in event-free-survival. The R1507-resistant tumors, OS31, and
OS33 were found to have low level and no IGF-1R expression,
respectively, by western blotting. However, despite the low receptor
expression, there is still evidence of an effect on signaling illustrated
through an induction of MAPK phosphorylation. Conclusions about
relative expression of IGF-1R using comparative immunoblotting
are limited and not as reliable as the receptor quantification
methodology utilized by Cao et al. Nonetheless, given the data
presented above, it would appear that alternate signaling through
MAPK may be more informative of IGF-1R resistance in these
osteosarcoma xenograft tumors. Our work demonstrates that IGF-
1R expression is necessary but not sufficient to predict response
to IGF-1R inhibition. Activation of alternative proliferation and
survival pathways including MAPK may play a role in resistance to
IGF-1R inhibition.
The OS1 and OS17 tumors were observed for 6 weeks following
treatment with R1507. In neither of these tumors was there an
increase in tumor growth rate following discontinuation of the drug.
It is reasonable to hypothesize that under the influence of R1507,
the cells invoke an alternative signaling pathway and that this
pathway maintains the oncogenic growth signals. In OS17, growth
is permitted, but is apparently less efficient. Furthermore, it is
possible, given these data, that the salvage signaling changes
induced by IGF-1R inhibition are long-standing or even permanent,
suggesting altered expression of signaling pathway mediators.
These hypotheses are currently under investigation.
The significance of identifying markers that will predict whether
a tumor is sensitive or resistant to IGF-1R-directed therapy cannot
be overstated. Clearly, in Figure 1, there is a subset of osteosarcoma
tumors that is sensitive to IGF-1R-directed therapy and a subset that
is resistant, regardless of receptor expression. In rhabdomyosar-
coma cell lines, treatment with rapamycin induces phosphorylation
of AKT. mTOR inhibits cap-dependent translation and, in doing so,
has the potential to inhibit expression of receptor tyrosine kinases
PI3K and AKT [15]. Releasing this negative feedback signal with
rapamycin has the potential to increase signaling through AKT
allowing increased expression and activation of upstream signal
mediators or AKT itself. AKT may also be directly phosphorylated
through the mTOR/rictor complex, which is less susceptible to
inhibition by rapamycin. In osteosarcoma, the current report
demonstrates that this increase in AKT phosphorylation is depend-
ent on IGF-1R signaling. Further studies are needed to confirm
whether it is possible for IGF-1R-independent signaling through
Ras to provide a means for osteosarcoma to salvage growth
signaling in the presence of IGF-1R signal inhibition. Increased
signaling through the Ras/MAPK pathway may be mediated though
an activating mutation within the components of the Ras pathway or
through alterations in upstream signaling pathways.
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